Drug Database
TA

tamsulosin (Hanmi Tams / tamsulosin, Hanmi / HIP 1402)

✓ Approved

Hanmi Pharmaceutical · ADRA1A · Small Molecule

What is tamsulosin?

tamsulosin is a small molecule developed by Hanmi Pharmaceutical. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesHanmi Tams, tamsulosin, Hanmi, HIP 1402
CompanyHanmi Pharmaceutical
Drug ClassSmall Molecule
Molecular TargetADRA1A
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Hanmi Pharmaceutical

Mechanism of Action

Molecular Targets

tamsulosin acts on 1 molecular target:

ADRA1Aadrenoceptor alpha 1A (ALPHA1AAR, ADRA1C)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

tamsulosin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Reproductive system and breast disordersBenign prostatic hyperplasia✓ Approved

Related Research Articles

PubMedAmerican journal of translational research2026-08-22

A retrospective cohort study on the improvement of urodynamic parameters and NIH-CPSI scores with Relin granules in BPH patients with high prostatitis-like symptom scores.

Xu Xiaoming X, Qu Jihui J, Hu Xiaokai X

To investigate the efficacy of Relin Granules combined with conventional therapy in improving urodynamic parameters, symptom scores, and inflammatory biomarkers in patients with benign prostatic hyperplasia (BPH) who have high prostatitis-like symptoms. This retrospective cohort study enrolled 132 BPH patients with a National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total score ≥15 who were treated between January 2023 and January 2025. Among them, 44 patients received conventional therapy plus Relin Granules (4 g tid, 12 weeks), and 88 received conventional therapy alone. Conventional treatment included the α-blocker tamsulosin and, in some patients, the 5α-reductase inhibitor finasteride. The primary outcomes were changes in NIH-CPSI, International Prostate Symptom Score (IPSS), and urodynamic parameters. After 12 weeks, the combination group showed significantly greater improvements in NIH-CPSI total score (adjusted difference -4.3, P<0.001), pain domain (-1.9, P<0.001) and quality of life domain (-1.4, P<0.001), while the urinary symptom domain did not differ significantly (P=0.056). Compared with the conventional group, the combination group had a greater reduction in IPSS total score (adjusted difference -2.1, P=0.004). No significant differences were observed in maximum flow rate (Qmax, adjusted difference 0.8 mL/s, P=0.342) or postvoid residual volume (PVR, 3.2 mL, P=0.415). The combination group showed significantly greater reductions in serum tumor necrosis factor-alpha (TNF-α) (adjusted difference -3.28 pg/mL, P<0.001) and urinary prostatic exosomal protein (PSEP) (-0.15 ng/mg, P=0.007), and a greater increase in interleukin-10 (IL-10) (1.89 pg/mL, P=0.012). Adverse event rates were similar (χ2=0.254, P=0.614). In BPH patients with high prostatitis-like symptoms, adding Relin Granules to conventional therapy was associated with alleviation of pain, improvement in quality of life and lower urinary tract symptoms (LUTS), potentially through anti-inflammatory mechanisms, with good safety.

PMID 42631160
Read full article →
PubMedGeorgian medical news2026-08-15

SAFETY OF TAMSULOSIN ALONE OR IN COMBINATION WITH 5Α-REDUCTASE INHIBITORS ON LIPID PROFILE, RENAL FUNCTION, AND LIVER PARAMETERS.

Sheet A A, Alnori M M

Tamsulosin and 5α-reductase inhibitors (finasteride and dutasteride) are widely prescribed for benign prostatic hyperplasia (BPH). However, their systemic effects on metabolic, renal, and hepatic functions remain incompletely understood. To evaluate the safety profile of tamsulosin monotherapy compared with combination therapies (tamsulosin plus finasteride or dutasteride) on lipid profile, renal function, liver enzymes, and bilirubin levels in men with BPH. This cross-sectional study included 102 male participants aged >50 years, divided into five groups: healthy controls (n=26), newly diagnosed treatment-naïve BPH (n=25), BPH receiving tamsulosin monotherapy >3 months (n=26), BPH receiving tamsulosin+finasteride >3 months (n=11), and BPH receiving tamsulosin+dutasteride >3 months (n=14). Serum lipid profile (total cholesterol, triglycerides, HDL-C, LDL-C, VLDL, atherogenic index), renal function (urea, creatinine, eGFR, uACR), liver function (ALT, AST, ALP, GGT, albumin), and bilirubin fractions (total, direct, indirect) were measured using standardized automated methods. Lipid profile parameters showed no significant differences between treatment groups and controls, with all values remaining within desirable ranges. Renal function tests, including serum urea, creatinine, eGFR, and urinary albumin-to-creatinine ratio, demonstrated no clinically significant alterations across all BPH treatment groups compared to controls. Liver enzymes (ALT, AST, ALP, GGT) and serum albumin levels remained within normal limits across all groups. Total, direct, and indirect bilirubin concentrations showed no significant elevation, indicating preserved hepatic excretory function. Notably, no statistically significant differences were observed between tamsulosin monotherapy and combination therapy groups for any of the measured parameters. Tamsulosin administered alone or in combination with finasteride or dutasteride for more than three months demonstrated non-significant differences in the measured biochemical parameters among the studied groups represented by no adverse effects on lipid metabolism, renal function, liver enzymes, or bilirubin homeostasis. These findings support the safe use of these therapeutic regimens in elderly BPH patients, including those with underlying metabolic or organ function concerns. Further prospective longitudinal studies with larger sample sizes are warranted to confirm these observations.

PMID 42603338
Read full article →
PubMedDiabetes research and clinical practice2026-08-07

Incidence of type 2 diabetes mellitus in men receiving finasteride and tamsulosin: a cross-validation cohort study using data from China and UK populations.

You Yile Y, Meng Xianglong X, Li Yuhao Y, Chen Jieying J et al.

To investigate the incidence of T2DM associated with finasteride and tamsulosin use in Chinese and UK populations. Using the Exchange Xiamen PLatform Of Resident E-health Records (EXPLORER) database in China and the UK Biobank (UKB), this study included men aged 40-80 years diagnosed with benign prostatic hyperplasia. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox models, incorporating overlap weighting. The EXPLORER cohort comprised 34,075 patients, with 21,399 untreated, 2,122 receiving finasteride monotherapy, 5,012 receiving tamsulosin monotherapy, and 5,542 receiving combination therapy. The UKB cohort comprised 11,905 patients, with 7,050 untreated, 492 receiving finasteride monotherapy, 3,105 receiving tamsulosin monotherapy, and 1,258 receiving combination therapy. Compared to patients receiving tamsulosin monotherapy, those receiving finasteride monotherapy showed a higher T2DM risk in the EXPLORER cohort (HR = 1.36 [95% CI: 1.15-1.60]), while no statistically significant association was observed in the UKB cohort (HR = 1.32 [95% CI: 0.96-1.82]). When compared to non-treatment, finasteride monotherapy was not associated with an elevated T2DM risk (EXPLORER: HR = 1.00 [95% CI: 0.89-1.13]; UKB: HR = 1.04 [95% CI: 0.77-1.41]), whereas tamsulosin monotherapy and combination therapy were associated with a reduced T2DM risk (EXPLORER: HR = 0.71 [95% CI: 0.64-0.80] and HR = 0.44 [95% CI: 0.40-0.49], respectively; UKB: HR = 0.67 [95% CI: 0.56-0.81] and HR = 0.45 [95% CI: 0.34-0.59], respectively). These findings suggest potential benefits of tamsulosin against T2DM and underscore the need for careful monitoring of T2DM risk in finasteride users.

PMID 42562182
Read full article →
PubMedDiabetes, obesity & metabolism2026-08-04

Absence of Interaction Between 5α-Reductase Inhibitors and Glucocorticoids on Incidence of Myocardial Infarction in People With Type 2 Diabetes.

Tu Haolan H, Ju Chengsheng C, McGurnaghan Stuart J SJ, Blackbourn Luke A K LAK et al.

People with Type 2 diabetes experience higher cardiometabolic risk, and both synthetic glucocorticoids and use of 5α-reductase inhibitors have been individually linked to increased risk of myocardial infarction. We tested whether the increase in risk is exacerbated by co-prescription of both drugs. We performed a population-based cohort study in the Scottish Diabetes Research Network-National Diabetes Dataset (SDRN-NDS) and IQVIA Medical Research Data-UK (IMRD-UK). Patients with Type 2 diabetes aged ≥ 40 years receiving 5α-reductase inhibitors or tamsulosin, who were incident users of systemic glucocorticoids during 2006-2021 were included. We modelled the joint effect of 5α-reductase inhibitors and cumulative exposure to glucocorticoids on the risk of myocardial infarction using a time-varying Cox proportional hazards model. A total of 13 161 patients with Type 2 diabetes were included in SDRN-NDS and 15 084 in IMRD-UK. Mean age was 71.4 ± 9.6 and 72.3 ± 9.4 years, with mean follow-up of 4.7 (3.6) and 5.6 (4.0) years, respectively. Median (IQR) total glucocorticoids exposure was 210 (96-630) and 420 (200-1240) prednisolone-equivalent milligram. Risk for myocardial infarction was increased among users of 5α-reductase inhibitors (HR [95% CI]: SDRN-NDS, 1.21 [1.02-1.43]; IMRD-UK, 1.27 [1.02-1.59]) and per SD increase in cumulative glucocorticoid exposure (HR [95% CI]: SDRN-NDS, 1.09 [1.03-1.14]; IMRD-UK, 1.08 [1.01-1.15]). We did not observe a multiplicative interaction (SDRN-NDS, p = 0.44; IMRD-UK, p = 0.68) between the use of the two drugs. People with Type 2 diabetes exposed to 5α-reductase inhibitors or glucocorticoids are at an increased risk of myocardial infarction, although a multiplicative interaction between the use of the two drugs was not found.

PMID 42547757
Read full article →
PubMedCureus2026-08-02

Painless Ischemic Priapism Associated With Tamsulosin Use: A Case Report and Literature Review.

Rector Caitlin E CE, Lei Kevin K, Hubbard Lael L, Ovasapians Navasard N et al.

Tamsulosin, a selective α1-adrenergic antagonist prescribed for benign prostatic hyperplasia and expulsion of ureteral stones, carries a rare risk of priapism. We present a 59-year-old male with hypogonadism, hypertension, and hyperlipidemia who developed painless priapism 72 hours after initiating tamsulosin for ureterolithiasis. Despite the atypical absence of pain, penile blood gas analysis confirmed ischemic priapism. Initial treatment with intracavernosal phenylephrine (1000 mcg) failed, requiring bilateral corpus spongiosum shunts for resolution. A literature review revealed that many of the 14 existing cases identified occurred within 24 hours of drug initiation in middle-aged or older patients without additional risk factors. Approximately half responded to intracavernosal vasoconstrictors, while refractory cases required surgical intervention. To our knowledge, this is the first reported case of painless tamsulosin-induced ischemic priapism, emphasizing the importance of patient counseling and prompt evaluation of persistent erections regardless of pain intensity.

PMID 42540804
Read full article →
PubMedAmerican journal of men's health2026-07-30

Concurrent Jackstone Calculus and Prostate Cancer: Should They Be Treated Concurrently or Sequentially?

Tian Shuo S, Li Huijuan H, Jiang Yuliang Y, Wang Cheng C et al.

Jackstone calculus is a rare urinary stone morphology with a distinctive spiculated appearance, most often reported in the bladder and usually associated with urinary stasis or outlet obstruction. We report a 70-year-old man with 1 year of progressive dysuria and intermittent interruption of urinary stream despite tamsulosin and finasteride. Urinalysis showed pyuria, hematuria, and bacteriuria. Ultrasonography and pelvic computed tomography identified an irregular star-shaped bladder stone and marked prostatic enlargement, with an estimated prostate volume of approximately 125 mL on ultrasonography. Serum total prostate-specific antigen was 16.2 ng/mL, with a free-to-total ratio of 0.138. Systematic transrectal biopsy showed adenocarcinoma in 2 of 12 cores, Gleason score 3 + 3 = 6 (Grade Group 1). After multidisciplinary discussion, the patient underwent laparoscopic radical prostatectomy with concomitant intact stone removal. The 3.1-cm stone showed classic jackstone morphology. Final pathology showed Gleason 3 + 4 = 7 adenocarcinoma (Grade Group 2), upgraded from biopsy, with negative surgical margins. Telephone follow-up at 1, 3, and 12 months showed sustained improvement of lower urinary tract symptoms without recurrent urinary tract infection-related symptoms. Postoperative imaging and prostate-specific antigen data were unavailable. This case is relevant to men's health because a visually distinctive bladder stone may coexist with clinically relevant prostatic disease. In men with lower urinary tract symptoms and abnormal prostate-specific antigen values, bladder outlet obstruction, infection, or bladder stones should not preclude further oncologic evaluation. In selected patients in whom definitive prostate surgery is chosen, combined stone removal can be a practical single-stage approach.

PMID 42531155
Read full article →

+2296 more articles available with a free account

Sign up free to view all articles →

Ask about tamsulosin